Vivos Therapeutics, Inc. (VVOS)
|Net Income (ttm)||-17.99M|
|Trading Day||April 19|
|Day's Range||8.06 - 8.60|
|52-Week Range||5.64 - 14.41|
Vivos Therapeutics Announces Integrative Cardiologist Dr. Mimi Guarneri as New Medical Director of Clinical Education
HIGHLANDS RANCH, Colo., April 14, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diag...
Vivos management to present at 9:00 am EDT on April 14, 2021 Vivos management to present at 9:00 am EDT on April 14, 2021
Vivos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update
Full Year Revenue Increase of 15%
Vivos management to present at 1:30 pm Eastern Time on March 23, 2021
Vivos Therapeutics Announces the Opening of the First Pneusomnia Integrated Medical-Dental Sleep Center
Physicians and Dentists Collaborate to Offer Vivos System Treatment to Patients Suffering from Sleep Apnea Physicians and Dentists Collaborate to Offer Vivos System Treatment to Patients Suffering from ...
If Approved for Clearance, Vivos' Updated Device Will Treat Mild to Moderate Sleep Apnea and Expand Insurance Reimbursement to include Medicare Coverage If Approved for Clearance, Vivos' Updated Device ...
Vivos Therapeutics Forms Clinical Advisory Board to Drive Further Growth of Next-Generation Obstructive Sleep Apnea T...
Internationally Recognized Medical and Dental Industry Veterans Will Work Closely with Vivos Management to Drive Further Commercial Success Internationally Recognized Medical and Dental Industry Veteran...
Cyclo Therapeutics (NASDAQ: CYTH) shares are trading higher Tuesday after the company announced "positive" efficacy data from an extension protocol with Trappsol Cyclo in patients with Niemann-Pick Dise...
Vivos Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to P...
HIGHLANDS RANCH, Colo., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos”) today announced the closing of its initial public offering of 4,025,000 shares of its common stock. The offer...
HIGHLANDS RANCH, Colo., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“ Vivos ”), a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate ...
Vivos Therapeutics, Inc., a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, today announced that is has filed a registrat...
Vivos Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ stock exchange.
Vivos Therapeutics is a revenue stage medical technology company focused on the development and commercialization of a highly differentiated technology offering a clinically effective non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). We offer novel and proprietary alternatives for treating mild-to-moderate OSA as well as certain craniofacial and anatomical anomalies known to be associated with mild-to-moderate OSA. W... [Read more...]
|IPO Date |
Dec 11, 2020
R. Kirk Huntsman
|Stock Exchange |
|Ticker Symbol |
In 2020, VVOS's revenue was $13.07 million, an increase of 14.68% compared to the previous year's $11.39 million. Losses were -$12.06 million, 12.1% more than in 2019.
According to 2 analysts, the average rating for VVOS stock is "Buy." The 12-month stock price forecast is 12.00, which is an increase of 47.24% from the latest price.